BCAX (Bicara Therapeutics) Payments of Debt: $0.00 Mil (TTM As of Mar. 2026)


BCAX Bicara Therapeutics Inc BCAX
12 GF Score
Price $28.01
! 3 Warning Signs
View Full Analysis

What is Bicara Therapeutics Payments of Debt?

Bicara Therapeutics BCAX +4.24% 12 Payments of Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates BCAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Bicara Therapeutics's Payments of Debt for the three months ended in Mar. 2026 was $0.00 Mil.

Bicara Therapeutics's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Bicara Therapeutics Payments of Debt Related Terms

Bicara Therapeutics Payments of Debt Historical Data

* Premium members only.

The historical data trend for Bicara Therapeutics's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics Payments of Debt Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Payments of Debt
0.00 0.00 0.00 0.00

Bicara Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BCAX
12GF Score
Bicara Therapeutics Inc BCAX
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicara Therapeutics Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $0.00 Mil mean?
Bicara Therapeutics (BCAX) has a Payments of Debt of $0.00 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Bicara Therapeutics and its competitors.
Is Bicara Therapeutics' Payments of Debt too high?
Bicara Therapeutics' current Payments of Debt is $0.00 Mil. Overall, Bicara Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' Payments of Debt compare to ZYME and SRPT?
Bicara Therapeutics' Payments of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Bicara Therapeutics and its competitors. Bicara Therapeutics's current Payments of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current Payments of Debt of $0.00 Mil. The current Payments of Debt is $0.00 Mil. Bicara Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current Payments of Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
12GF Score

Get the complete analysis for BCAX

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.01
Price